{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T15:23:01Z","timestamp":1789831381848,"version":"4.0.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,12,30]],"date-time":"2017-12-30T00:00:00Z","timestamp":1514592000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1007\/s10067-017-3966-1","type":"journal-article","created":{"date-parts":[[2017,12,30]],"date-time":"2017-12-30T01:43:21Z","timestamp":1514598201000},"page":"439-450","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Risk of serious infections in biological treatment of patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis"],"prefix":"10.1007","volume":"37","author":[{"given":"Sen","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongwen","family":"Shuai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,12,30]]},"reference":[{"issue":"4","key":"3966_CR1","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/art.1780270401","volume":"27","author":"S Linden van der","year":"1984","unstructured":"van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27(4):361\u2013368. \nhttps:\/\/doi.org\/10.1002\/art.1780270401","journal-title":"Arthritis Rheum"},{"issue":"6","key":"3966_CR2","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1136\/ard.2009.108233","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit M, van der Heijde D, Landewe R, Listing J, Akkoc N, Brandt J, Braun J, Chou CT, Collantes-Estevez E, Dougados M, Huang F, Gu J, Khan MA, Kirazli Y, Maksymowych WP, Mielants H, Sorensen IJ, Ozgocmen S, Roussou E, Valle-Onate R, Weber U, Wei J, Sieper J (2009) The development of assessment of SpondyloArthritis international society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 68(6):777\u2013783. \nhttps:\/\/doi.org\/10.1136\/ard.2009.108233","journal-title":"Ann Rheum Dis"},{"issue":"9570","key":"3966_CR3","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/S0140-6736(07)60635-7","volume":"369","author":"J Braun","year":"2007","unstructured":"Braun J, Sieper J (2007) Ankylosing spondylitis. Lancet 369(9570):1379\u20131390. \nhttps:\/\/doi.org\/10.1016\/S0140-6736(07)60635-7","journal-title":"Lancet"},{"issue":"2","key":"3966_CR4","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrrheum.2015.133","volume":"12","author":"MA Brown","year":"2016","unstructured":"Brown MA, Kenna T, Wordsworth BP (2016) Genetics of ankylosing spondylitis\u2014insights into pathogenesis. Nat Rev Rheumatol 12(2):81\u201391. \nhttps:\/\/doi.org\/10.1038\/nrrheum.2015.133","journal-title":"Nat Rev Rheumatol"},{"issue":"12","key":"3966_CR5","doi-asserted-by":"publisher","first-page":"4048","DOI":"10.1002\/art.21492","volume":"52","author":"N Akkoc","year":"2005","unstructured":"Akkoc N, Khan MA (2005) Overestimation of the prevalence of ankylosing spondylitis in the Berlin study: comment on the article by Braun et al. Arthritis Rheum 52(12):4048\u20134049. \nhttps:\/\/doi.org\/10.1002\/art.21492","journal-title":"Arthritis Rheum"},{"issue":"9","key":"3966_CR6","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1001\/2012.jama.10857","volume":"308","author":"MA Lopez-Olivo","year":"2012","unstructured":"Lopez-Olivo MA, Tayar JH, Martinez-Lopez JA, Pollono EN, Cueto JP, Gonzales-Crespo MR, Fulton S, Suarez-Almazor ME (2012) Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. JAMA 308(9):898\u2013908. \nhttps:\/\/doi.org\/10.1001\/2012.jama.10857","journal-title":"JAMA"},{"issue":"6","key":"3966_CR7","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1136\/ard.2011.151027","volume":"70","author":"J Braun","year":"2011","unstructured":"Braun J, van den Berg R, Baraliakos X, Boehm H, Burgos-Vargas R, Collantes-Estevez E, Dagfinrud H, Dijkmans B, Dougados M, Emery P, Geher P, Hammoudeh M, Inman R, Jongkees M, Khan M, Kiltz U, Kvien T, Leirisalo-Repo M, Maksymowych W, Olivieri I, Pavelka K, Sieper J, Stanislawska-Biernat E, Wendling D, Ozgocmen S, van Drogen C, van Royen B, van der Heijde D (2011) 2010 update of the ASAS\/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 70(6):896\u2013904. \nhttps:\/\/doi.org\/10.1136\/ard.2011.151027","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"3966_CR8","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1093\/rheumatology\/41.11.1330","volume":"41","author":"B Roychowdhury","year":"2002","unstructured":"Roychowdhury B, Bintley-Bagot S, Bulgen DY, Thompson RN, Tunn EJ, Moots RJ (2002) Is methotrexate effective in ankylosing spondylitis? Rheumatology (Oxford) 41(11):1330\u20131332. \nhttps:\/\/doi.org\/10.1093\/rheumatology\/41.11.1330","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"3966_CR9","doi-asserted-by":"publisher","first-page":"e000397","DOI":"10.1136\/rmdopen-2016-000397","volume":"3","author":"A Regel","year":"2017","unstructured":"Regel A, Sepriano A, Baraliakos X, van der Heijde D, Braun J, Landew\u00e9 R, van den Bosch F, Falzon L, Ramiro S (2017) Efficacy and safety of non-pharmacological and non-biological pharmacological treatment: a systematic literature review informing the 2016 update of the ASAS\/EULAR recommendations for the management of axial spondyloarthritis. RMD Open 3(1):e000397. \nhttps:\/\/doi.org\/10.1136\/rmdopen-2016-000397","journal-title":"RMD Open"},{"issue":"1","key":"3966_CR10","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1186\/s12891-015-0805-x","volume":"16","author":"GJ Macfarlane","year":"2015","unstructured":"Macfarlane GJ, Barnish MS, Jones EA, Kay L, Keat A, Meldrum KT, Pathan E, Sturrock RD, Zabke C, McNamee P, Jones GT (2015) The British Society for Rheumatology Biologics Registers in Ankylosing Spondylitis (BSRBR-AS) study: protocol for a prospective cohort study of the long-term safety and quality of life outcomes of biologic treatment. BMC Musculoskelet Disord 16(1):347. \nhttps:\/\/doi.org\/10.1186\/s12891-015-0805-x","journal-title":"BMC Musculoskelet Disord"},{"issue":"3","key":"3966_CR11","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1136\/annrheumdis-2013-204577","volume":"73","author":"JL Nam","year":"2014","unstructured":"Nam JL, Ramiro S, Gaujoux-Viala C, Takase K, Leon-Garcia M, Emery P, Gossec L, Landewe R, Smolen JS, Buch MH (2014) Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 73(3):516\u2013528. \nhttps:\/\/doi.org\/10.1136\/annrheumdis-2013-204577","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"3966_CR12","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1002\/art.23606","volume":"58","author":"H Haibel","year":"2008","unstructured":"Haibel H, Rudwaleit M, Listing J, Heldmann F, Wong RL, Kupper H, Braun J, Sieper J (2008) Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. Arthritis Rheum 58(7):1981\u20131991. \nhttps:\/\/doi.org\/10.1002\/art.23606","journal-title":"Arthritis Rheum"},{"issue":"6","key":"3966_CR13","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1002\/art.11017","volume":"48","author":"J Brandt","year":"2003","unstructured":"Brandt J, Khariouzov A, Listing J, Haibel H, S\u00f6rensen H, Grassnickel L, Rudwaleit M, Sieper J, Braun J (2003) Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 48(6):1667\u20131675. \nhttps:\/\/doi.org\/10.1002\/art.11017","journal-title":"Arthritis Rheum"},{"issue":"4","key":"3966_CR14","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1002\/art.24408","volume":"60","author":"N Barkham","year":"2009","unstructured":"Barkham N, Keen HI, Coates LC, O'Connor P, Hensor E, Fraser AD, Cawkwell LS, Bennett A, McGonagle D, Emery P (2009) Clinical and imaging efficacy of infliximab in HLA-B27-positive patients with magnetic resonance imaging-determined early sacroiliitis. Arthritis Rheum 60(4):946\u2013954. \nhttps:\/\/doi.org\/10.1002\/art.24408","journal-title":"Arthritis Rheum"},{"issue":"9","key":"3966_CR15","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1093\/rheumatology\/keu132","volume":"53","author":"C Bao","year":"2014","unstructured":"Bao C, Huang F, Khan MA, Fei K, Wu Z, Han C, Hsia EC (2014) Safety and efficacy of golimumab in Chinese patients with active ankylosing spondylitis: 1-year results of a multicentre, randomized, double-blind, placebo-controlled phase III trial. Rheumatology (Oxford) 53(9):1654\u20131663. \nhttps:\/\/doi.org\/10.1093\/rheumatology\/keu132","journal-title":"Rheumatology (Oxford)"},{"issue":"9906","key":"3966_CR16","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1016\/S0140-6736(13)61134-4","volume":"382","author":"D Baeten","year":"2013","unstructured":"Baeten D, Baraliakos X, Braun J, Sieper J, Emery P, van der Heijde D, McInnes I, van Laar JM, Landew\u00e9 R, Wordsworth P, Wollenhaupt J, Kellner H, Paramarta J, Wei J, Brachat A, Bek S, Laurent D, Li Y, Wang YA, Bertolino AP, Gsteiger S, Wright AM, Hueber W (2013) Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet 382(9906):1705\u20131713. \nhttps:\/\/doi.org\/10.1016\/S0140-6736(13)61134-4","journal-title":"Lancet"},{"issue":"1","key":"3966_CR17","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1136\/annrheumdis-2013-204231","volume":"73","author":"R Landewe","year":"2014","unstructured":"Landewe R, Braun J, Deodhar A et al (2014) Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled phase 3 study. Ann Rheum Dis 73(1):39\u201347. \nhttps:\/\/doi.org\/10.1136\/annrheumdis-2013-204231","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"3966_CR18","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1136\/annrheumdis-2013-203559","volume":"73","author":"J Sieper","year":"2014","unstructured":"Sieper J, Porter-Brown B, Thompson L, Harari O, Dougados M (2014) Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials. Ann Rheum Dis 73(1):95\u2013100. \nhttps:\/\/doi.org\/10.1136\/annrheumdis-2013-203559","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"3966_CR19","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1136\/annrheumdis-2013-204963","volume":"74","author":"J Sieper","year":"2015","unstructured":"Sieper J, Braun J, Kay J, Badalamenti S, Radin AR, Jiao L, Fiore S, Momtahen T, Yancopoulos GD, Stahl N, Inman RD (2015) Sarilumab for the treatment of ankylosing spondylitis: results of a phase II, randomised, double-blind, placebo-controlled study (ALIGN). Ann Rheum Dis 74(6):1051\u20131057. \nhttps:\/\/doi.org\/10.1136\/annrheumdis-2013-204963","journal-title":"Ann Rheum Dis"},{"key":"3966_CR20","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.cyto.2017.02.015","volume":"96","author":"I Cludts","year":"2017","unstructured":"Cludts I, Spinelli FR, Morello F, Hockley J, Valesini G, Wadhwa M (2017) Anti-therapeutic antibodies and their clinical impact in patients treated with the TNF antagonist adalimumab. Cytokine 96:16\u201323. \nhttps:\/\/doi.org\/10.1016\/j.cyto.2017.02.015","journal-title":"Cytokine"},{"issue":"9","key":"3966_CR21","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1093\/rheumatology\/kem166","volume":"46","author":"X Baraliakos","year":"2007","unstructured":"Baraliakos X, Listing J, Brandt J, Haibel H, Rudwaleit M, Sieper J, Braun J (2007) Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF-alpha antibody infliximab. Rheumatology (Oxford) 46(9):1450\u20131453. \nhttps:\/\/doi.org\/10.1093\/rheumatology\/kem166","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"3966_CR22","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1002\/art.30223","volume":"63","author":"J Braun","year":"2011","unstructured":"Braun J, van der Horst-Bruinsma IE, Huang F, Burgos-Vargas R, Vlahos B, Koenig AS, Freundlich B (2011) Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial. Arthritis Rheum 63(6):1543\u20131551. \nhttps:\/\/doi.org\/10.1002\/art.30223","journal-title":"Arthritis Rheum"},{"issue":"11","key":"3966_CR23","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1136\/ard.2004.022582","volume":"64","author":"H Marzo-Ortega","year":"2005","unstructured":"Marzo-Ortega H, McGonagle D, Jarrett S, Haugeberg G, Hensor E, O'connor P, Tan AL, Conaghan PG, Greenstein A, Emery P (2005) Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study. Ann Rheum Dis 64(11):1568\u20131575. \nhttps:\/\/doi.org\/10.1136\/ard.2004.022582","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"3966_CR24","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.berh.2014.10.001","volume":"28","author":"PD Sampaio-Barros","year":"2014","unstructured":"Sampaio-Barros PD, van der Horst-Bruinsma IE (2014) Adverse effects of TNF inhibitors in SpA: are they different from RA? Best Pract Res Clin Rheumatol 28(5):747\u2013763. \nhttps:\/\/doi.org\/10.1016\/j.berh.2014.10.001","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"12","key":"3966_CR25","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1007\/s00296-016-3575-3","volume":"36","author":"Y Ozguler","year":"2016","unstructured":"Ozguler Y, Hatemi G, Ugurlu S, Seyahi E, Melikoglu M, Borekci S, Atahan E, Ongen G, Hamuryudan V (2016) Re-initiation of biologics after the development of tuberculosis under anti-TNF therapy. Rheumatol Int 36(12):1719\u20131725. \nhttps:\/\/doi.org\/10.1007\/s00296-016-3575-3","journal-title":"Rheumatol Int"},{"issue":"9990","key":"3966_CR26","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/S0140-6736(14)61704-9","volume":"386","author":"JA Singh","year":"2015","unstructured":"Singh JA, Cameron C, Noorbaloochi S, Cullis T, Tucker M, Christensen R, Ghogomu ET, Coyle D, Clifford T, Tugwell P, Wells GA (2015) Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet 386(9990):258\u2013265. \nhttps:\/\/doi.org\/10.1016\/S0140-6736(14)61704-9","journal-title":"Lancet"},{"issue":"19","key":"3966_CR27","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","volume":"295","author":"T Bongartz","year":"2006","unstructured":"Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295(19):2275\u20132285. \nhttps:\/\/doi.org\/10.1001\/jama.295.19.2275","journal-title":"JAMA"},{"issue":"1","key":"3966_CR28","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1136\/ard.2007.083188","volume":"68","author":"C Salliot","year":"2009","unstructured":"Salliot C, Dougados M, Gossec L (2009) Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis 68(1):25\u201332. \nhttps:\/\/doi.org\/10.1136\/ard.2007.083188","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"3966_CR29","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1002\/art.30310","volume":"63","author":"AE Thompson","year":"2011","unstructured":"Thompson AE, Rieder SW, Pope JE (2011) Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis Rheum 63(6):1479\u20131485. \nhttps:\/\/doi.org\/10.1002\/art.30310","journal-title":"Arthritis Rheum"},{"issue":"10","key":"3966_CR30","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1136\/ard.2008.098822","volume":"69","author":"A Fouque-Aubert","year":"2010","unstructured":"Fouque-Aubert A, Jette-Paulin L, Combescure C, Basch A, Tebib J, Gossec L (2010) Serious infections in patients with ankylosing spondylitis with and without TNF blockers: a systematic review and meta-analysis of randomised placebo-controlled trials. Ann Rheum Dis 69(10):1756\u20131761. \nhttps:\/\/doi.org\/10.1136\/ard.2008.098822","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"3966_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"AR Jadad","year":"1996","unstructured":"Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, McQuay HJ (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17(1):1\u201312. \nhttps:\/\/doi.org\/10.1016\/0197-2456(95)00134-4","journal-title":"Control Clin Trials"},{"issue":"9313","key":"3966_CR32","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/S0140-6736(02)08215-6","volume":"359","author":"J Braun","year":"2002","unstructured":"Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, Gromnica-lhle E, Kellner H, Krause A, Schneider M, S\u00f6rensen H, Zeidler H, Thriene W, Sieper J (2002) Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 359(9313):1187\u20131193. \nhttps:\/\/doi.org\/10.1016\/S0140-6736(02)08215-6","journal-title":"Lancet"},{"issue":"18","key":"3966_CR33","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1056\/NEJMoa012664","volume":"346","author":"JD Gorman","year":"2002","unstructured":"Gorman JD, Sack KE, Davis JC Jr (2002) Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 346(18):1349\u20131356. \nhttps:\/\/doi.org\/10.1056\/NEJMoa012664","journal-title":"N Engl J Med"},{"issue":"3","key":"3966_CR34","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1002\/art.511","volume":"46","author":"F Bosch Van Den","year":"2002","unstructured":"Van Den Bosch F, Kruithof E, Baeten D et al (2002) Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy. Arthritis Rheum 46(3):755\u2013765. \nhttps:\/\/doi.org\/10.1002\/art.511","journal-title":"Arthritis Rheum"},{"key":"3966_CR35","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1002\/art.11325","volume":"48","author":"JC Davis Jr","year":"2003","unstructured":"Davis JC Jr, Van Der Heijde D, Braun J et al (2003) Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 48:3230\u20133236","journal-title":"Arthritis Rheum"},{"issue":"12","key":"3966_CR36","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1136\/ard.2004.020875","volume":"63","author":"A Calin","year":"2004","unstructured":"Calin A, Dijkmans BA, Emery P, Hakala M, Kalden J, Leirisalo-Repo M, Mola EM, Salvarani C, Sanmart\u00ed R, Sany J, Sibilia J, Sieper J, van der Linden S, Veys E, Appel AM, Fatenejad S (2004) Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 63(12):1594\u20131600. \nhttps:\/\/doi.org\/10.1136\/ard.2004.020875","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"3966_CR37","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1002\/art.20852","volume":"52","author":"D Heijde van der","year":"2005","unstructured":"van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, Braun J, Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group (2005) Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 52(2):582\u2013591. \nhttps:\/\/doi.org\/10.1002\/art.20852","journal-title":"Arthritis Rheum"},{"issue":"12","key":"3966_CR38","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1136\/ard.2006.056747","volume":"65","author":"D Heijde van der","year":"2006","unstructured":"van der Heijde D, Da Silva JC, Dougados M, Geher P, van der Horst-Bruinsma I, Juanola X, Olivieri I, Raeman F, Settas L, Sieper J, Szechinski J, Walker D, Boussuge MP, Wajdula JS, Paolozzi L, Fatenejad S, for the Etanercept Study 314 Investigators (2006) Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis. Ann Rheum Dis 65(12):1572\u20131577. \nhttps:\/\/doi.org\/10.1136\/ard.2006.056747","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"3966_CR39","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1002\/art.21913","volume":"54","author":"D Heijde van der","year":"2006","unstructured":"van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BAC, Braun J, Dougados M, Reveille JD, Wong RL, Kupper H, Davis JC, ATLAS Study Group (2006) Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 54(7):2136\u20132146. \nhttps:\/\/doi.org\/10.1002\/art.21913","journal-title":"Arthritis Rheum"},{"issue":"11","key":"3966_CR40","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1002\/art.23969","volume":"58","author":"RD Inman","year":"2008","unstructured":"Inman RD, Davis JC Jr, Heijde D et al (2008) Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 58(11):3402\u20133412. \nhttps:\/\/doi.org\/10.1002\/art.23969","journal-title":"Arthritis Rheum"},{"issue":"5","key":"3966_CR41","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1136\/ard.2010.139261","volume":"70","author":"M Dougados","year":"2011","unstructured":"Dougados M, Braun J, Szanto S, Combe B, Elbaz M, Geher P, Thabut G, Leblanc V, Logeart I (2011) Efficacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis: results of a randomised double-blind placebo-controlled study (SPINE). Ann Rheum Dis 70(5):799\u2013804. \nhttps:\/\/doi.org\/10.1136\/ard.2010.139261","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"3966_CR42","doi-asserted-by":"publisher","first-page":"R230","DOI":"10.1186\/ar4072","volume":"14","author":"G Horneff","year":"2012","unstructured":"Horneff G, Fitter S, Foeldvari I, Minden K, Kuemmerle-Deschner J, Tzaribacev N, Thon A, Borte M, Ganser G, Trauzeddel R, Huppertz HI (2012) Double-blind, placebo-controlled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): significant short term improvement. Arthritis Res Ther 14(5):R230. \nhttps:\/\/doi.org\/10.1186\/ar4072","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"3966_CR43","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1136\/annrheumdis-2012-201766","volume":"72","author":"J Sieper","year":"2013","unstructured":"Sieper J, van der Heijde D, Dougados M, Mease PJ, Maksymowych WP, Brown MA, Arora V, Pangan AL (2013) Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Ann Rheum Dis 72(6):815\u2013822. \nhttps:\/\/doi.org\/10.1136\/annrheumdis-2012-201766","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"3966_CR44","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1002\/art.38721","volume":"66","author":"M Dougados","year":"2014","unstructured":"Dougados M, van der Heijde D, Sieper J, Braun J, Maksymowych WP, Citera G, Miceli-Richard C, Wei JCC, Pedersen R, Bonin R, Rahman MU, Logeart I, Wajdula J, Koenig AS, Vlahos B, Alvarez D, Bukowski JF (2014) Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol 66(8):2091\u20132102. \nhttps:\/\/doi.org\/10.1002\/art.38721","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"3966_CR45","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1136\/annrheumdis-2012-202533","volume":"73","author":"F Huang","year":"2014","unstructured":"Huang F, Gu J, Zhu P, Bao C, Xu J, Xu H, Wu H, Wang G, Shi Q, Andhivarothai N, Anderson J, Pangan AL (2014) Efficacy and safety of adalimumab in Chinese adults with active ankylosing spondylitis: results of a randomised, controlled trial. Ann Rheum Dis 73(3):587\u2013594. \nhttps:\/\/doi.org\/10.1136\/annrheumdis-2012-202533","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"3966_CR46","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1136\/annrheumdis-2012-203201","volume":"73","author":"J Sieper","year":"2014","unstructured":"Sieper J, Lenaerts J, Wollenhaupt J, Rudwaleit M, Mazurov VI, Myasoutova L, Park S, Song Y, Yao R, Chitkara D, Vastesaeger N, on Behalf of All INFAST Investigators (2014) Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, part 1. Ann Rheum Dis 73(1):101\u2013107. \nhttps:\/\/doi.org\/10.1136\/annrheumdis-2012-203201","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"3966_CR47","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1136\/ard.2005.040758","volume":"65","author":"J Braun","year":"2006","unstructured":"Braun J, Davis J, Dougados M, Sieper J, van der Linden S, van der Heijde D (2006) First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 65(3):316\u2013320. \nhttps:\/\/doi.org\/10.1136\/ard.2005.040758","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"3966_CR48","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1136\/annrheumdis-2013-204011","volume":"74","author":"H Yun","year":"2015","unstructured":"Yun H, Xie F, Delzell E, Chen L, Levitan EB, Lewis JD, Saag KG, Beukelman T, Winthrop K, Baddley JW, Curtis JR (2015) Risk of hospitalised infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapy. Ann Rheum Dis 74(6):1065\u20131071. \nhttps:\/\/doi.org\/10.1136\/annrheumdis-2013-204011","journal-title":"Ann Rheum Dis"},{"key":"3966_CR49","doi-asserted-by":"crossref","first-page":"j895","DOI":"10.1136\/bmj.j895","volume":"356","author":"RJ Desai","year":"2017","unstructured":"Desai RJ, Bateman BT, Huybrechts KF et al (2017) Risk of serious infections associated with use of immunosuppressive agents in pregnant women with autoimmune inflammatory conditions: cohort study. BMJ 356:j895","journal-title":"BMJ"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-017-3966-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-017-3966-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-017-3966-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,20]],"date-time":"2018-01-20T01:53:53Z","timestamp":1516413233000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-017-3966-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,30]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["3966"],"URL":"https:\/\/doi.org\/10.1007\/s10067-017-3966-1","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,30]]}}}